[Meta-analysis of Platelet Lymphocyte Ratio As A Prognostic Factor For Non-small Cell Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2019 May 22

PMID 31109438

Citations 3

Authors

Haoran Chen

Hao Xue

Wenjing Liu

Fangfang Wu

Yituo Wang

Hongjun Gao

Affiliations

Soon will be listed here.

Abstract

Background: Current research shows that platelet to lymphocyte ratio (PLR) has important prognostic value in renal cell carcinoma, esophageal cancer, gastric cancer, liver cancer and colon cancer. The aim of the study is to evaluate the prognostic value of PLR in non-small cell lung cancer (NSCLC) through meta-analysis.

Methods: Literature search for PubMed, EMBASE, Web of Science, Medline, Cochrane Library, China National Knowledge Internet (CNKI), China Biomedical Medicine disc (CBMdisc), VIP, Wanfang Database using computer electronic system to study the association between PLR and overall survival (OS) and disease-free survival (DFS). Each eligible study data is extracted and a meta-analysis is performed using the hazard risk (HR) and 95% confidence interval (95%CI) to assess the prognostic value of PLR, the time limit for the search is to build the library until November 2018.

Results: We include a total of 15 research literatures involving 5,524 patients for meta-analysis. According to the results of the meta-analysis: The OS of the higher PLR group is significantly lower than that of the lower PLR group (HR=1.69, 95%CI: 1.45-1.97, P<0.000,01, I²=46.2%, Pheterogeneity=0.026); the DFS of the higher PLR group is significantly lower than that of the lower PLR group (HR=1.41, 95%CI: 1.14-1.74, P=0.001, I²=46.2%, Pheterogeneity=0.026). Subgroup analysis show that the OS of the higher PLR group is still significantly lower than the lower PLR group (P<0.05) after grouping by ethnicity, sample size, PLR cutoff value and treatment.

Conclusions: Increased PLR is associated with poor prognosis in NSCLC, so PLR may be an important biological predictive marker for NSCLC patients, however, its clinical application still needs to be verified through more research in the future.

Citing Articles

Evaluation of Haematological Parameters and Uric Acid in the Diagnosis of Late Onset Neonatal Sepsis.

Yilmaz Oztorun Z Cureus. 2023; 15(5):e39691.

PMID: 37398776 PMC: 10308802. DOI: 10.7759/cureus.39691.

Preoperative Neutrophil Lymphocyte Ratio Can Be Used as a Predictor of Prognosis in Patients With Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta Analysis.

Liu X, Gao Z, Zhang Q, Pandey S, Gao B, Yang F Front Oncol. 2020; 10:178.

PMID: 32154173 PMC: 7046751. DOI: 10.3389/fonc.2020.00178.

Platelet to Lymphocyte Ratio in Neonates: A Predictor of Early onset Neonatal Sepsis.

Arcagok B, Karabulut B Mediterr J Hematol Infect Dis. 2019; 11(1):e2019055.

PMID: 31528321 PMC: 6736225. DOI: 10.4084/MJHID.2019.055.

References

Shi L, Wang L, Hou J, Zhu B, Min Z, Zhang M . Targeting roles of inflammatory microenvironment in lung cancer and metastasis. Cancer Metastasis Rev. 2015; 34(2):319-31. DOI: 10.1007/s10555-015-9570-4. View

Powell C, Halmos B, Nana-Sinkam S . Update in lung cancer and mesothelioma 2012. Am J Respir Crit Care Med. 2013; 188(2):157-66. PMC: 3778761. DOI: 10.1164/rccm.201304-0716UP. View

Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C . Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg. 2015; 210(3):526-35. DOI: 10.1016/j.amjsurg.2015.03.022. View

Pinato D, Shiner R, Seckl M, Stebbing J, Sharma R, Mauri F . Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 2014; 110(8):1930-5. PMC: 3992503. DOI: 10.1038/bjc.2014.145. View

Dutta S, Crumley A, Fullarton G, Horgan P, McMillan D . Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011; 35(8):1861-6. DOI: 10.1007/s00268-011-1130-7. View

Alexandrakis M, Passam F, Moschandrea I, Christophoridou A, Pappa C, Coulocheri S . Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol. 2003; 26(2):135-40. DOI: 10.1097/00000421-200304000-00007. View

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A . Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?. Asian Pac J Cancer Prev. 2013; 14(9):5237-42. DOI: 10.7314/apjcp.2013.14.9.5237. View

10.

Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X . Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer. 2015; 6(3):275-87. PMC: 4448393. DOI: 10.1111/1759-7714.12178. View

11.

Kos M, Hocazade C, Kos F, Uncu D, Karakas E, Dogan M . Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer. Wien Klin Wochenschr. 2015; 128(17-18):635-40. DOI: 10.1007/s00508-015-0724-8. View

12.

Yi F, Gu Y, Chen S, Liu Y, Yin W, Zhang Y . [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2018; 21(6):481-492. PMC: 6022033. DOI: 10.3779/j.issn.1009-3419.2018.06.02. View

13.

McMillan D . The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2012; 39(5):534-40. DOI: 10.1016/j.ctrv.2012.08.003. View

14.

Toda M, Tsukioka T, Izumi N, Komatsu H, Okada S, Hara K . Platelet-to-lymphocyte ratio predicts the prognosis of patients with non-small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy. Thorac Cancer. 2017; 9(1):112-119. PMC: 5754286. DOI: 10.1111/1759-7714.12547. View

15.

Fox P, Hudson M, Brown C, Lord S, Gebski V, de Souza P . Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013; 109(1):147-53. PMC: 3708579. DOI: 10.1038/bjc.2013.300. View

16.

Menter D, Tucker S, Kopetz S, Sood A, Crissman J, Honn K . Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014; 33(1):231-69. PMC: 4186918. DOI: 10.1007/s10555-014-9498-0. View

17.

Kawashima M, Murakawa T, Shinozaki T, Ichinose J, Hino H, Konoeda C . Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery. Interact Cardiovasc Thorac Surg. 2015; 21(5):637-43. DOI: 10.1093/icvts/ivv223. View

18.

Sanchez-Lara K, Turcott J, Juarez E, Guevara P, Nunez-Valencia C, Onate-Ocana L . Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 2012; 64(4):526-34. DOI: 10.1080/01635581.2012.668744. View

19.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W . Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017; 111:176-181. DOI: 10.1016/j.lungcan.2017.07.024. View

20.

Jurasz P, Alonso-Escolano D, Radomski M . Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004; 143(7):819-26. PMC: 1575943. DOI: 10.1038/sj.bjp.0706013. View

[Meta-analysis of Platelet Lymphocyte Ratio As A Prognostic Factor For Non-small Cell Lung Cancer]

[Meta-analysis of Platelet Lymphocyte Ratio As A Prognostic Factor For Non-small Cell Lung Cancer]